member shares history with the research team
Original official website text record
Share this clinical trial paper that we recently published in Lancet Regional Health. This journal just got a score this year and is expected to have a chance to break through 20 points next year. This is a new JAK inhibitor, used to treat Chinese data on rheumatoid arthritis. It was sponsored by a Japanese pharmaceutical company. I participated in the design and planning, and was the result of a cross-border collaboration executed in mainland China. The results of the study: The effectiveness is roughly similar to the results in Western countries, but the new information is that the side effects of herpes zoster in Chinese areas are not that high. In other words, the safety of this new drug is relatively better.
Further reading:Original data (open in another window)
Return to Research and Education